Joshua Boger joins Alkeus Pharmaceuticals as executive chairman

Friday, May 25, 2012 01:21 PM

Alkeus Pharmaceuticals of Boston, Mass., has appointed Joshua Boger, Ph.D., as executive chairman of the company's board of directors. 

Bringing over 30 years of experience in drug discovery, development and commercialization, Boger founded Vertex Pharmaceuticals in 1989, and before that worked for over a decade at Merck.

As CEO of Vertex, he led the company's efforts to develop science-based, transformative medicines, which have since turned the company into a successful global business. Besides leading the way in the use of structure-based rational drug design as the basis for drug discovery, Boger pioneered alliances between pharma companies and disease-focused foundations by partnering with the Cystic Fibrosis Foundation to discover and develop new cystic fibrosis medicines. This resulted early 2012 in the marketing approval of Vertex’s first cystic fibrosis medicine, one of the first oral drugs to address the root cause of a genetic condition.

Beyond his role as executive chairman of Alkeus, Boger will continue to serve on the board of Vertex, as well as chair of the board of fellows of the Harvard Medical School, chair of the board of trustees at Wesleyan University, chair of NEHI (the Network for Healthcare Innovation, Cambridge), board member of the Biotechnology Industry Organization (BIO), the Whitehead Institute for Biomedical Research, the Hastings Center and the Massachusetts Life Sciences Center.

 

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs